MX2018003663A - Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. - Google Patents
Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2.Info
- Publication number
- MX2018003663A MX2018003663A MX2018003663A MX2018003663A MX2018003663A MX 2018003663 A MX2018003663 A MX 2018003663A MX 2018003663 A MX2018003663 A MX 2018003663A MX 2018003663 A MX2018003663 A MX 2018003663A MX 2018003663 A MX2018003663 A MX 2018003663A
- Authority
- MX
- Mexico
- Prior art keywords
- ovary
- sccoht
- rhabdoid tumor
- small cell
- cell cancer
- Prior art date
Links
- 208000008938 Rhabdoid tumor Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 210000001672 ovary Anatomy 0.000 title abstract 3
- 230000000121 hypercalcemic effect Effects 0.000 title abstract 2
- 208000000649 small cell carcinoma Diseases 0.000 title abstract 2
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 201000003612 hypercalcemic type ovarian small cell carcinoma Diseases 0.000 title 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 abstract 2
- 229950004774 tazemetostat Drugs 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233146P | 2015-09-25 | 2015-09-25 | |
| US201562252188P | 2015-11-06 | 2015-11-06 | |
| PCT/US2016/053673 WO2017053930A2 (en) | 2015-09-25 | 2016-09-26 | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018003663A true MX2018003663A (es) | 2018-08-14 |
Family
ID=58387531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003663A MX2018003663A (es) | 2015-09-25 | 2016-09-26 | Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. |
| MX2022013390A MX2022013390A (es) | 2015-09-25 | 2018-03-23 | Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013390A MX2022013390A (es) | 2015-09-25 | 2018-03-23 | Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20180296563A1 (enExample) |
| EP (1) | EP3352761A4 (enExample) |
| JP (1) | JP7013369B2 (enExample) |
| KR (1) | KR20180054793A (enExample) |
| CN (2) | CN114533880B (enExample) |
| AU (2) | AU2016325643B2 (enExample) |
| CA (1) | CA2999898A1 (enExample) |
| EA (1) | EA201890801A1 (enExample) |
| IL (2) | IL258302A (enExample) |
| MX (2) | MX2018003663A (enExample) |
| SG (1) | SG10201908323TA (enExample) |
| WO (1) | WO2017053930A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| AU2016325643B2 (en) * | 2015-09-25 | 2022-07-21 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| WO2017214373A1 (en) * | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| JP2019521988A (ja) | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| EP3576729A4 (en) * | 2017-02-02 | 2021-04-14 | Epizyme, Inc. | CANCER TREATMENT MODALITIES |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| EP3678663A4 (en) | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | POLYTHERAPY FOR CANCER TREATMENT |
| CN113874013A (zh) * | 2019-03-26 | 2021-12-31 | 转化药物开发有限责任公司 | 治疗卵巢恶性横纹肌样瘤和高钙血症型卵巢小细胞癌的方法 |
| JP2022545467A (ja) * | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN115666725A (zh) * | 2020-05-28 | 2023-01-31 | Epizyme股份有限公司 | Ezh2抑制剂用于治疗癌症的用途 |
| CN115786261B (zh) * | 2022-11-28 | 2024-12-06 | 复旦大学附属妇产科医院 | 一种卵巢高钙血症型小细胞癌细胞系及其用途 |
| CN119215165A (zh) * | 2023-06-29 | 2024-12-31 | 复旦大学附属妇产科医院 | Plk1抑制剂在制备治疗卵巢高钙血症型小细胞癌的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2614369T3 (pl) * | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| EP2709629B1 (en) * | 2011-05-16 | 2017-10-11 | Ulrike Nuber | Novel cancer therapies and methods |
| EP2825161B1 (en) * | 2012-03-12 | 2019-01-02 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| CN104768555B (zh) * | 2012-04-13 | 2018-10-30 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
| MX376008B (es) * | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| US20140120083A1 (en) * | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015103431A1 (en) * | 2013-12-31 | 2015-07-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function |
| EA201691872A1 (ru) * | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
| MX2018002344A (es) * | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| AU2016325643B2 (en) * | 2015-09-25 | 2022-07-21 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type |
-
2016
- 2016-09-26 AU AU2016325643A patent/AU2016325643B2/en not_active Ceased
- 2016-09-26 MX MX2018003663A patent/MX2018003663A/es unknown
- 2016-09-26 EP EP16849837.6A patent/EP3352761A4/en not_active Withdrawn
- 2016-09-26 SG SG10201908323T patent/SG10201908323TA/en unknown
- 2016-09-26 KR KR1020187011111A patent/KR20180054793A/ko not_active Ceased
- 2016-09-26 WO PCT/US2016/053673 patent/WO2017053930A2/en not_active Ceased
- 2016-09-26 CN CN202210048334.0A patent/CN114533880B/zh active Active
- 2016-09-26 CN CN201680063541.6A patent/CN108349958B/zh active Active
- 2016-09-26 US US15/762,839 patent/US20180296563A1/en not_active Abandoned
- 2016-09-26 JP JP2018515673A patent/JP7013369B2/ja not_active Expired - Fee Related
- 2016-09-26 EA EA201890801A patent/EA201890801A1/ru unknown
- 2016-09-26 CA CA2999898A patent/CA2999898A1/en not_active Abandoned
-
2018
- 2018-03-22 IL IL258302A patent/IL258302A/en unknown
- 2018-03-23 MX MX2022013390A patent/MX2022013390A/es unknown
-
2019
- 2019-10-04 US US16/593,010 patent/US20200138825A1/en not_active Abandoned
-
2020
- 2020-09-03 US US17/011,132 patent/US20210121470A1/en not_active Abandoned
-
2021
- 2021-02-09 IL IL280760A patent/IL280760A/en unknown
-
2022
- 2022-10-19 AU AU2022256115A patent/AU2022256115A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016325643B2 (en) | 2022-07-21 |
| KR20180054793A (ko) | 2018-05-24 |
| US20200138825A1 (en) | 2020-05-07 |
| AU2022256115A1 (en) | 2022-11-17 |
| CN114533880A (zh) | 2022-05-27 |
| JP2018529698A (ja) | 2018-10-11 |
| CN114533880B (zh) | 2023-08-22 |
| WO2017053930A3 (en) | 2018-04-12 |
| AU2016325643A1 (en) | 2018-04-12 |
| IL280760A (en) | 2021-04-29 |
| EP3352761A4 (en) | 2019-04-24 |
| US20210121470A1 (en) | 2021-04-29 |
| CN108349958A (zh) | 2018-07-31 |
| JP7013369B2 (ja) | 2022-02-15 |
| MX2022013390A (es) | 2023-01-04 |
| WO2017053930A2 (en) | 2017-03-30 |
| EP3352761A2 (en) | 2018-08-01 |
| EA201890801A1 (ru) | 2018-09-28 |
| IL258302A (en) | 2018-05-31 |
| CA2999898A1 (en) | 2017-03-30 |
| US20180296563A1 (en) | 2018-10-18 |
| SG10201908323TA (en) | 2019-10-30 |
| CN108349958B (zh) | 2022-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013390A (es) | Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. | |
| PH12018502263A1 (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| MX2021004881A (es) | Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno. | |
| MX2019012038A (es) | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. | |
| PH12015502855B1 (en) | Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations | |
| CA2919397C (en) | Aryl ethers as hif-2.alpha. inhibitors for the treatment of cancer | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| ZA201802966B (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| SG10201909413SA (en) | Method of treating medulloblastoma with an ezh2 inhibitor | |
| WO2017100362A3 (en) | Inhibitors of ezh2 and methods of use thereof | |
| EA201691748A1 (ru) | Антитела анти-cd38 для лечения острого лимфобластного лейкоза | |
| SG10201903356XA (en) | Method for treating cancer | |
| MA40076A (fr) | Inhibiteurs de syk | |
| MY201580A (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor | |
| EP4552698A3 (en) | Methods of treating prostate cancer | |
| BR112019024719A2 (pt) | Composições e métodos para resposta imunológica antitumor aprimorada | |
| SG10201900564WA (en) | Methods for treating cancer | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019004940A (es) | Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| GB2569488A (en) | PD-1 specific aptamers | |
| MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. |